Charles L. Bisgaier
Charles L. Bisgaier publishes mostly in Molecular Biology, Surgery and Endocrinology, Diabetes and Metabolism, on topics such as Lipoproteins and Cardiovascular Health, Peroxisome Proliferator-Activated Receptors and Diabetes, Cardiovascular Risks, and Lipoproteins.
- World rank
- #714,569 of 7,710,434 ranked researchers
- Rank in United States
- #241,118 of 1,627,098
- Works
- 71
- Citations
- 5.3k
- Citations per work
- 74.1
What does Charles L. Bisgaier research?
Charles L. Bisgaier's work is mostly in Biochemistry, Genetics and Molecular Biology (34%), Medicine (26%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else2839.2%
- Life Sciences2434.3%
- Health Sciences1926.5%
- Medicine1926.5%
- 1Molecular Biology24% of their works
- 2Surgery14% of their works
- 3Endocrinology, Diabetes and Metabolism6% of their works
- 4Physiology6% of their works
- 5Biochemistry5% of their works
- 6Clinical Biochemistry5% of their works
Research topics
- Lipoproteins and Cardiovascular Health
- Peroxisome Proliferator-Activated Receptors
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Paraoxonase enzyme and polymorphisms
- Atherosclerosis and Cardiovascular Diseases
- RNA Interference and Gene Delivery
- Cholesterol and Lipid Metabolism
- Cynara cardunculus studies
Which keywords describe Charles L. Bisgaier's research?
The keywords of their largest research topics: Atherosclerosis, Inflammation, Diabetes, Obesity, Cholesterol-lowering, Metabolism, Statins and Cardiovascular Disease.
- Artichoke
- SREBP
- LXR
- Immune Response
- Oxidative Stress
- Glucose Metabolism
- Peroxisome Proliferator-Activated Receptors
- Metabolic Syndrome
- Cardiovascular Disease
- Metabolism
- Obesity
- Inflammation
- Atherosclerosis
- Diabetes
- Cholesterol-lowering
- Statins
- Cholesterol
- PPARs
- HDL
- Insulin Resistance
- Paraoxonase
- Oxidized LDL
- RNA Interference
- siRNA Delivery
- Phenolic Compounds
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 25 words, with their numbers
- Atherosclerosis304 topics
- Inflammation293 topics
- Diabetes262 topics
- Obesity262 topics
- Cholesterol-lowering201 topic
- Metabolism202 topics
- Statins201 topic
- Cardiovascular Disease192 topics
- Cholesterol162 topics
- Metabolic Syndrome152 topics
- PPARs151 topic
- Peroxisome Proliferator-Activated Receptors151 topic
- HDL132 topics
- Glucose Metabolism111 topic
- Insulin Resistance111 topic
- Oxidative Stress81 topic
- Paraoxonase81 topic
- Immune Response61 topic
- Oxidized LDL61 topic
- LXR51 topic
- RNA Interference51 topic
- SREBP51 topic
- siRNA Delivery51 topic
- Artichoke41 topic
- Phenolic Compounds41 topic
Where does Charles L. Bisgaier work?
Charles L. Bisgaier's main affiliation in the publication record is Esperion Therapeutics (United States), United States.
How many publications and citations does Charles L. Bisgaier have?
OpenAlex counts 71 works and 5,258 citations for Charles L. Bisgaier, an h-index of 29, ranking #714,569 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Charles L. Bisgaier. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.